As of 2025-10-16, the Intrinsic Value of Neurocrine Biosciences Inc (NBIX) is 158.08 USD. This NBIX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 137.73 USD, the upside of Neurocrine Biosciences Inc is 14.80%.
The range of the Intrinsic Value is 109.59 - 302.51 USD
Based on its market price of 137.73 USD and our intrinsic valuation, Neurocrine Biosciences Inc (NBIX) is undervalued by 14.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 109.59 - 302.51 | 158.08 | 14.8% |
| DCF (Growth 10y) | 148.69 - 392.32 | 210.22 | 52.6% |
| DCF (EBITDA 5y) | 121.72 - 147.56 | 134.28 | -2.5% |
| DCF (EBITDA 10y) | 152.13 - 190.65 | 170.41 | 23.7% |
| Fair Value | 87.79 - 87.79 | 87.79 | -36.26% |
| P/E | 51.90 - 88.67 | 66.72 | -51.6% |
| EV/EBITDA | 75.42 - 124.30 | 97.05 | -29.5% |
| EPV | 40.17 - 49.15 | 44.66 | -67.6% |
| DDM - Stable | 25.04 - 62.05 | 43.55 | -68.4% |
| DDM - Multi | 39.83 - 77.63 | 52.74 | -61.7% |
| Market Cap (mil) | 13,660.06 |
| Beta | 0.65 |
| Outstanding shares (mil) | 99.18 |
| Enterprise Value (mil) | 13,396.06 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.96% |
| Cost of Debt | 4.25% |
| WACC | 7.02% |